Lupin unveils smoking cessation tablets Varenicline in US
It is indicated for use as an aid to smoking cessation treatment.
Mumbai: Global pharma major Lupin Limited has announced the launch of Varenicline Tablets, 0.5 mg and 1 mg, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Read also: Lupin bags USFDA nod for Varenicline Tablets for smoking cessation treatment
Varenicline Tablets, 0.5 mg and 1 mg is the generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. It is indicated for use as an aid to smoking cessation treatment.
Varenicline Tablets (RLD Chantix) had estimated annual sales of USD 412 million in the U.S. (IQVIA MAT November 2023).
Read also: Lupin bags tentative USFDA nod for Dapagliflozin and Saxagliptin Tablets
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.
Read also: Lupin unveils Bromfenac Ophthalmic Solution in US
